A Case of Hydroxychloroquine Induced Hypoglycaemia in a Non-Diabetic Patient

Richard, De-Heer; Doherty, Teresa

doi:10.23937/2469-5726/1510066

Cited by 2 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, this class may be used in resistant depression (Yamada & Yasuhara, 2004). No interaction has been reported between MAOIs and hydroxychloroquine, but several articles reported the hypoglycemic effect of MAOIs (Cooper & Ashcroft, 1966;Wickström & Pettersson, 1964) and hydroxychloroquine (Cansu & Korkmaz, 2008;De-Heer & Doherty, 2018;Shojania, Koehler, & Elliott, 1999;Unübol et al, 2011). Hypothetically, their co-administration may lead to hypoglycemia.…”

Section: Monoamine Oxidase Inhibitors (Maois)mentioning

confidence: 99%

Drug Interactions of Psychiatric and COVID-19 Medications

Mohebbi

Talebi

Moghadamnia

et al. 2020

Basic Clin. Neurosci. J.

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) has become a pandemic with 1771514 cases identified in the world and 70029 cases in Iran until April 12, 2020. The co-prescription of psychotropics with COVID-19 medication is not uncommon. Healthcare providers should be familiar with many Potential Drug-Drug Interactions (DDIs) between COVID-19 therapeutic agents and psychotropic drugs based on cytochrome P450 metabolism. This review comprehensively summarizes the current literature on DDIs between antiretroviral drugs and chloroquine/hydroxychloroquine, and psychotropics, including antidepressants, antipsychotics, mood stabilizers, and anxiolytics. Methods: Medical databases, including Google Scholar, PubMed, Web of Science, and Scopus were searched to identify studies in English with keywords related to psychiatric disorders, medications used in the treatment of psychiatric disorders and COVID-19 medications. Results: There is a great potential for DDIs between psychiatric and COVID-19 medications ranging from interactions that are not clinically apparent (minor) to those that produce lifethreatening adverse drug reactions, or loss of treatment efficacy. The majority of interactions are pharmacokinetic interactions via the cytochrome P450 enzyme system. Conclusion: DDIs are a major concern in the comorbidity of psychiatric disorders and COVID-19 infection resulting in the alteration of expected therapeutic outcomes. The risk of toxicity or lack of efficacy may occur due to a higher or lower plasma concentration of medications. However, psychiatric medication can be safely used in combination with COVID-19 pharmacotherapy with either a wise selection of medication with the least possibility of interaction or careful patient monitoring and management.

show abstract

Section: Monoamine Oxidase Inhibitors (Maois)mentioning

confidence: 99%

Drug Interactions of Psychiatric and COVID-19 Medications

Mohebbi

Talebi

Moghadamnia

et al. 2020

Basic Clin. Neurosci. J.

View full text Add to dashboard Cite

show abstract

“…Hypoglycemia is yet another serious side effect exerted, albeit rarely, by HCQ (Cansu and Korkmaz, 2008;Sheikhbahaie et al, 2016;Richard De-Heer, 2018). Indeed, evidence stemming from both in vitro and clinical studies underscores the role of HCQ in reducing blood glucose levels.…”

Section: Serious Side Effects Of Hydroxychloroquinementioning

confidence: 99%

Hydroxychloroquine in COVID-19 Patients: Pros and Cons

et al. 2020

View full text Add to dashboard Cite

The pandemic of COVID-19, caused by SARS-CoV-2, has recently overwhelmed medical centers and paralyzed economies. The unparalleled public distress caused by this pandemic mandated an urgent quest for an effective approach to manage or treat this disease. Due to their well-established anti-infectious and anti-inflammatory properties, quinine derivatives have been sought as potential therapies for COVID-19. Indeed, these molecules were originally employed in the treatment and prophylaxis of malaria, and later in the management of various autoimmune rheumatic and dermatologic diseases. Initially, some promising results for the use of hydroxychloroquine (HCQ) in treating COVID-19 patients were reported by a few in vitro and in vivo studies. However, current evidence is not yet sufficiently solid to warrant its use as a therapy for this disease. Additionally, the therapeutic effects of HCQ are not without many side effects, which range from mild gastrointestinal effects to life-threatening cardiovascular and neurological effects. In this review, we explore the controversy associated with the repurposing of HCQ to manage or treat COVID-19, and we discuss the cellular and molecular mechanisms of action of HCQ.

show abstract

A Case of Hydroxychloroquine Induced Hypoglycaemia in a Non-Diabetic Patient

Cited by 2 publications

References 12 publications

Drug Interactions of Psychiatric and COVID-19 Medications

Drug Interactions of Psychiatric and COVID-19 Medications

Hydroxychloroquine in COVID-19 Patients: Pros and Cons

Contact Info

Product

Resources

About